A5031890333- Prostate Cancer Treatment and Research
- Cancer Immunotherapy and Biomarkers
- Cancer, Lipids, and Metabolism
- Renal cell carcinoma treatment
- Radiopharmaceutical Chemistry and Applications
- Prostate Cancer Diagnosis and Treatment
- Immunotherapy and Immune Responses
- PARP inhibition in cancer therapy
- Cancer Genomics and Diagnostics
- Palliative Care and End-of-Life Issues
- Cancer Treatment and Pharmacology
- Bladder and Urothelial Cancer Treatments
- Ferroptosis and cancer prognosis
- Cancer-related molecular mechanisms research
- Patient-Provider Communication in Healthcare
- CAR-T cell therapy research
- Renal and related cancers
- Cancer survivorship and care
- Protein Hydrolysis and Bioactive Peptides
- Childhood Cancer Survivors' Quality of Life
- Hormonal and reproductive studies
- vaccines and immunoinformatics approaches
- Heat shock proteins research
- Microtubule and mitosis dynamics
- Glioma Diagnosis and Treatment
Beth Israel Deaconess Medical Center
2016-2025
Harvard University
2018-2024
Dana-Farber Cancer Institute
2020-2024
Hadassah Medical Center
2023-2024
Beth Israel Deaconess Hospital
2021
Boston College
2017
Massachusetts General Hospital
2017
Tufts Medical Center
2012-2016
AIDS Research Consortium of Atlanta
2016
Tufts University
2016
To determine the value of tumor cell programmed death-ligand 1 (PD-L1) expression as a predictive biomarker nivolumab monotherapy efficacy in treatment-naive patients with clear renal carcinoma (ccRCC) and salvage nivolumab/ipilimumab tumors unresponsive to monotherapy.
439 Background: Cisplatin-based neoadjuvant chemotherapy (NAC) in MIBC improves survival which correlates with pathologic response (PaR) at radical cystectomy (RC). The combination of immunotherapy and NAC may improve PaR outcomes MIBC. We tested the efficacy safety nivolumab (N) gemcitabine-cisplatin (GC) as therapy for our phase II trial (NCT03294304). Methods: Eligible pts (cT2-T4a, N≤1, M0) who were candidates RC enrolled. Pts received C (70mg/m2) IV on D1, G (1000mg/m2) D1,D8 N (360 mg)...
The role of immune-oncologic mechanisms racial disparities in prostate cancer remains understudied. Limited research exists to evaluate the molecular underpinnings immune differences African American men (AAM) and European (EAM) tumor microenvironment (TME).A total 1,173 radiation-naïve radical prostatectomy samples with whole transcriptome data from Decipher GRID registry were used. Transcriptomic expressions 1,260 immune-specific genes selected assess between AAM EAM tumors. Race-specific...
This multicenter randomized phase 2 trial investigates the impact of intense androgen deprivation on radical prostatectomy pathologic response and radiographic tissue biomarkers in localized prostate cancer (NCT02903368).Eligible patients had a Gleason score ≥4+3=7, specific antigen >20 ng/mL or T3 disease lymph nodes <20 mm. In Part 1, were 1:1 to apalutamide, abiraterone acetate, prednisone leuprolide (AAPL) abiraterone, prednisone, (APL) for 6 cycles (1 cycle=28 days) followed by...
Despite decreased screening-based detection of clinically insignificant tumors, most diagnosed prostate cancers are still indolent, indicating a need for better strategies significant disease before treatment. We hypothesized that patients with detectable circulating tumor DNA (ctDNA) were more likely to harbor aggressive disease.
Abstract Wnt signaling driven by genomic alterations in genes including APC and CTNNB, which encodes β-catenin, have been implicated prostate cancer development progression to metastatic castration-resistant (mCRPC). However, nongenomic drivers downstream effectors of the therapeutic potential targeting this pathway not fully established. Here we analyzed Wnt/β-catenin identified distinct from those found other tissues, aryl hydrocarbon receptor RUNX1, are linked stem cell maintenance, ROR1,...
Background To determine the efficacy and toxicity of nivolumab monotherapy in treatment-naïve patients with non-clear cell renal carcinoma (nccRCC) nivolumab/ipilimumab salvage therapy tumors unresponsive to initial monotherapy. Methods Eligible nccRCC received until progressive disease (PD), toxicity, or completion 96 weeks treatment (Part A). Patients PD prior to, stable (SD) at 48 (prolonged SD) were potentially eligible receive B). required submit tissue from a metastatic lesion obtained...
Abstract Background Patients with localized, unfavorable intermediate–risk and high‐risk prostate cancer have an increased risk of relapse after radical prostatectomy (RP). The authors previously reported on part 1 this phase 2 trial testing neoadjuvant apalutamide, abiraterone, prednisone, plus leuprolide (AAPL) or (APL) for 6 months followed by RP. results demonstrated favorable pathologic responses (tumor <5 mm) in 20.3% patients ( n = 24 118). Herein, the report 2. Methods For 2, were...
303 Background: Six months of a GnRH agonist with SRT is standard care for patients unfavorable features and detectable PSA post-RP. FORMULA-509 was designed to evaluate whether adding six AAP Apa this regimen could improve outcomes. Methods: (NCT03141671) an investigator-initiated, multi-center, open-label, randomized trial. Patients had PSA≥0.1 post-RP one or more (Gleason 8-10, PSA>0.5, pT3/T4, pN1 radiographic N1, doubling time <10 months, negative margins, persistent PSA, gross...
Background As part of a partitioned survival analysis, treatment-free (TFS) can characterize the overall time patients spend between cessation immunotherapy and start subsequent therapy; both with without toxicity. Significant TFS was reported for nivolumab/ipilimumab arms CheckMate 067 214 trials advanced melanoma or renal cell carcinoma (aRCC), respectively, where often halted toxicity rather than predefined treatment endpoint. We therefore sought to assess in HCRN GU16-260 trial, which...
What is most important to patients with BCR prostate cancer? Metastasis-free versus treatment-free survival.
150 Background: Treatment of a BCR typically starts with androgen-deprivation therapy (ADT), which is limited by treatment-emergent adverse events (TEAEs) that adversely impact patients’ quality life. The second-generation androgen receptor inhibitors (ARIs), enzalutamide and apalutamide, were explored in patients BCR, demonstrating reduction prostate-specific antigen (PSA) but an increase testosterone levels from baseline at week 25 114% 134% (1,2). Given the strong efficacy favorable...
To identify the safety of niraparib, a PARP inhibitor, in combination with Radium-223 for treatment metastatic castrate-resistant prostate cancer (mCRPC) men without known BRCA mutations.
Purpose of review Patients with biochemically recurrent prostate cancer (BCR) after unsuccessful curative therapies frequently have an indolent and asymptomatic disease course for years. There are no prospective data showing that treating BCR improves overall survival despite new imaging strategies emerging therapeutic data. Managing requires a unique perspective in oncology balances toxicities kinetics. Recent findings Prostate specific membrane antigen (PSMA) is now widely available can...
Autologous therapeutic tumor-infiltrating lymphocyte (TIL) therapy is a promising strategy to enhance antitumor immunity. Optimization of ex vivo TIL expansion could expand current immunotherapy options. Previous attempts generate in renal cell carcinoma (RCC) have been technically challenging. We applied second-generation manufacturing process, currently used the melanoma product lifileucel, RCC. Resected primary and metastatic RCC samples were processed using Gen 2 process comprising...
Patients with advanced cancer benefit from early involvement of palliative care. The ideal method care integration remains to be determined, as does its effectiveness for patients treated targeted and immune-based therapies.We studied the impact an embedded team that saw in academic oncology clinic specializing therapies. seen on a specific day accessed model, basis automatic criteria; other days could referred separate (usual care). We abstracted data medical records 114 who died during 3...